Clinically, it has been shown that elevated pre-treatment CXCL9 and CXCL10 levels correlate with the response to anti-PD-L 1 therapy in patients with non-small cell lung cancer, and CXCL9 and CXCL10 increase in the first months of treatment in melanoma patients responding to PD-1 inhibitor therapy. Here, CXCL9 is linked to melanoma.